Compare Cytokinetics Inc (CYTK) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs HCA Health Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while HCA Health Inc trades at $411.81 (market cap $89.64B). The key difference: HCA Health Inc is far larger — about 8.3× Cytokinetics Inc's market cap, and HCA Health Inc pays a 0.75% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | HCA | |
|---|---|---|
Market Cap | $10.78B | $89.64B |
Sector | Technology | Health |
52-Week High | $87.26 | $545.13 |
52-Week Low | $34.31 | $361.32 |
Enterprise Value | $10.88B | $140.18B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.
The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
